ID   NRK1_HUMAN              Reviewed;         199 AA.
AC   Q9NWW6; Q5W124; Q8N430;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   12-APR-2017, entry version 125.
DE   RecName: Full=Nicotinamide riboside kinase 1;
DE            Short=NRK 1;
DE            Short=NmR-K 1;
DE            EC=2.7.1.22 {ECO:0000269|PubMed:17914902, ECO:0000269|PubMed:8809081};
DE   AltName: Full=Nicotinic acid riboside kinase 1;
DE            EC=2.7.1.173 {ECO:0000269|PubMed:17914902, ECO:0000269|PubMed:8809081};
DE   AltName: Full=Ribosylnicotinamide kinase 1;
DE            Short=RNK 1;
DE   AltName: Full=Ribosylnicotinic acid kinase 1;
GN   Name=NMRK1; Synonyms=C9orf95, NRK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=15137942; DOI=10.1016/S0092-8674(04)00416-7;
RA   Bieganowski P., Brenner C.;
RT   "Discoveries of nicotinamide riboside as a nutrient and conserved NRK
RT   genes establish a Preiss-Handler independent route to NAD+ in fungi
RT   and humans.";
RL   Cell 117:495-502(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Colon, and Hippocampus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.
RC   TISSUE=Placenta;
RX   PubMed=8809081; DOI=10.1006/abbi.1996.0409;
RA   Sasiak K., Saunders P.P.;
RT   "Purification and properties of a human nicotinamide ribonucleoside
RT   kinase.";
RL   Arch. Biochem. Biophys. 333:414-418(1996).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.32 ANGSTROMS) OF 2-189 IN COMPLEXES WITH ATP
RP   AND SUBSTRATES, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   AND MUTAGENESIS OF ASP-36 AND GLU-98.
RX   PubMed=17914902; DOI=10.1371/journal.pbio.0050263;
RA   Tempel W., Rabeh W.M., Bogan K.L., Belenky P., Wojcik M., Seidle H.F.,
RA   Nedyalkova L., Yang T., Sauve A.A., Park H.-W., Brenner C.;
RT   "Nicotinamide riboside kinase structures reveal new pathways to
RT   NAD+.";
RL   PLoS Biol. 5:2220-2230(2007).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) IN COMPLEXES WITH NUCLEOSIDE
RP   MONOPHOSPHATE; ADP AND TIAZOFURIN, AND MUTAGENESIS OF LYS-16; ASP-36;
RP   ASP-56 AND ASP-138.
RX   PubMed=17698003; DOI=10.1016/j.str.2007.06.017;
RA   Khan J.A., Xiang S., Tong L.;
RT   "Crystal structure of human nicotinamide riboside kinase.";
RL   Structure 15:1005-1013(2007).
CC   -!- FUNCTION: Catalyzes the phosphorylation of nicotinamide riboside
CC       (NR) and nicotinic acid riboside (NaR) to form nicotinamide
CC       mononucleotide (NMN) and nicotinic acid mononucleotide (NaMN). The
CC       enzyme also phosphorylates the antitumor drugs tiazofurin and 3-
CC       deazaguanosine. {ECO:0000269|PubMed:15137942}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1-(beta-D-ribofuranosyl)-nicotinamide =
CC       ADP + beta-nicotinamide D-ribonucleotide.
CC       {ECO:0000269|PubMed:17914902, ECO:0000269|PubMed:8809081}.
CC   -!- CATALYTIC ACTIVITY: ATP + beta-D-ribosylnicotinate = ADP +
CC       nicotinate beta-D-ribonucleotide. {ECO:0000269|PubMed:17914902,
CC       ECO:0000269|PubMed:8809081}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.088 mM for nicotinamide riboside (with ATP as cosubstrate)
CC         {ECO:0000269|PubMed:17914902, ECO:0000269|PubMed:8809081};
CC         KM=0.068 mM for nicotinamide riboside (with GTP as cosubstrate)
CC         {ECO:0000269|PubMed:17914902, ECO:0000269|PubMed:8809081};
CC         KM=0.27 mM for tiazofurin (with ATP as cosubstrate)
CC         {ECO:0000269|PubMed:17914902, ECO:0000269|PubMed:8809081};
CC         KM=0.051 mM for nicotinic acid riboside (with ATP as
CC         cosubstrate) {ECO:0000269|PubMed:17914902,
CC         ECO:0000269|PubMed:8809081};
CC         KM=17 mM for uridine (with ATP as cosubstrate)
CC         {ECO:0000269|PubMed:17914902, ECO:0000269|PubMed:8809081};
CC       pH dependence:
CC         Optimum pH is 6.5-9. {ECO:0000269|PubMed:17914902,
CC         ECO:0000269|PubMed:8809081};
CC   -!- PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis.
CC       {ECO:0000305|PubMed:17914902}.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:8809081}.
CC   -!- INTERACTION:
CC       Q86VP1:TAX1BP1; NbExp=5; IntAct=EBI-10315485, EBI-529518;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NWW6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NWW6-2; Sequence=VSP_012676;
CC         Note=No experimental confirmation available.;
CC   -!- SIMILARITY: Belongs to the uridine kinase family. NRK subfamily.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY611480; AAT11928.1; -; mRNA.
DR   EMBL; AK000566; BAA91259.1; -; mRNA.
DR   EMBL; AL133548; CAH71570.1; -; Genomic_DNA.
DR   EMBL; AL133548; CAH71571.1; -; Genomic_DNA.
DR   EMBL; CH471089; EAW62568.1; -; Genomic_DNA.
DR   EMBL; BC001366; AAH01366.1; -; mRNA.
DR   EMBL; BC036804; AAH36804.1; -; mRNA.
DR   CCDS; CCDS47981.1; -. [Q9NWW6-2]
DR   CCDS; CCDS6650.1; -. [Q9NWW6-1]
DR   RefSeq; NP_001121075.1; NM_001127603.1. [Q9NWW6-2]
DR   RefSeq; NP_001317607.1; NM_001330678.1.
DR   RefSeq; NP_060351.1; NM_017881.2. [Q9NWW6-1]
DR   RefSeq; XP_006717226.1; XM_006717163.2. [Q9NWW6-1]
DR   RefSeq; XP_016870359.1; XM_017014870.1. [Q9NWW6-1]
DR   RefSeq; XP_016870363.1; XM_017014874.1. [Q9NWW6-2]
DR   UniGene; Hs.494186; -.
DR   PDB; 2P0E; X-ray; 1.80 A; A=2-189.
DR   PDB; 2QG6; X-ray; 1.50 A; A=1-199.
DR   PDB; 2QL6; X-ray; 2.70 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=1-199.
DR   PDB; 2QSY; X-ray; 1.95 A; A=2-189.
DR   PDB; 2QSZ; X-ray; 1.90 A; A=2-189.
DR   PDB; 2QT0; X-ray; 1.92 A; A=2-189.
DR   PDB; 2QT1; X-ray; 1.32 A; A=2-189.
DR   PDBsum; 2P0E; -.
DR   PDBsum; 2QG6; -.
DR   PDBsum; 2QL6; -.
DR   PDBsum; 2QSY; -.
DR   PDBsum; 2QSZ; -.
DR   PDBsum; 2QT0; -.
DR   PDBsum; 2QT1; -.
DR   ProteinModelPortal; Q9NWW6; -.
DR   SMR; Q9NWW6; -.
DR   BioGrid; 120317; 2.
DR   IntAct; Q9NWW6; 3.
DR   STRING; 9606.ENSP00000354387; -.
DR   iPTMnet; Q9NWW6; -.
DR   PhosphoSitePlus; Q9NWW6; -.
DR   BioMuta; NMRK1; -.
DR   DMDM; 50401180; -.
DR   EPD; Q9NWW6; -.
DR   MaxQB; Q9NWW6; -.
DR   PaxDb; Q9NWW6; -.
DR   PeptideAtlas; Q9NWW6; -.
DR   PRIDE; Q9NWW6; -.
DR   DNASU; 54981; -.
DR   Ensembl; ENST00000361092; ENSP00000354387; ENSG00000106733. [Q9NWW6-1]
DR   Ensembl; ENST00000376808; ENSP00000366004; ENSG00000106733. [Q9NWW6-2]
DR   GeneID; 54981; -.
DR   KEGG; hsa:54981; -.
DR   UCSC; uc004ajr.5; human. [Q9NWW6-1]
DR   CTD; 54981; -.
DR   GeneCards; NMRK1; -.
DR   HGNC; HGNC:26057; NMRK1.
DR   HPA; HPA049795; -.
DR   MIM; 608704; gene.
DR   neXtProt; NX_Q9NWW6; -.
DR   OpenTargets; ENSG00000106733; -.
DR   PharmGKB; PA134946592; -.
DR   eggNOG; KOG3308; Eukaryota.
DR   eggNOG; COG0572; LUCA.
DR   GeneTree; ENSGT00510000046782; -.
DR   HOGENOM; HOG000043899; -.
DR   HOVERGEN; HBG052669; -.
DR   InParanoid; Q9NWW6; -.
DR   KO; K10524; -.
DR   PhylomeDB; Q9NWW6; -.
DR   TreeFam; TF105395; -.
DR   BRENDA; 2.7.1.173; 2681.
DR   Reactome; R-HSA-196807; Nicotinate metabolism.
DR   UniPathway; UPA00253; -.
DR   ChiTaRS; NMRK1; human.
DR   EvolutionaryTrace; Q9NWW6; -.
DR   GenomeRNAi; 54981; -.
DR   PRO; PR:Q9NWW6; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000106733; -.
DR   CleanEx; HS_C9orf95; -.
DR   ExpressionAtlas; Q9NWW6; baseline and differential.
DR   Genevisible; Q9NWW6; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0050262; F:ribosylnicotinamide kinase activity; EXP:Reactome.
DR   GO; GO:0061769; F:ribosylnicotinate kinase activity; EXP:Reactome.
DR   GO; GO:0009435; P:NAD biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0019674; P:NAD metabolic process; TAS:Reactome.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000764; Uridine_kinase-like.
DR   PRINTS; PR00988; URIDINKINASE.
DR   SUPFAM; SSF52540; SSF52540; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Kinase; Magnesium; Metal-binding; Nucleotide-binding;
KW   Pyridine nucleotide biosynthesis; Reference proteome; Transferase.
FT   CHAIN         1    199       Nicotinamide riboside kinase 1.
FT                                /FTId=PRO_0000215891.
FT   NP_BIND      10     18       ATP. {ECO:0000244|PDB:2P0E,
FT                                ECO:0000244|PDB:2QG6,
FT                                ECO:0000244|PDB:2QL6,
FT                                ECO:0000244|PDB:2QSY,
FT                                ECO:0000244|PDB:2QSZ,
FT                                ECO:0000244|PDB:2QT0,
FT                                ECO:0000244|PDB:2QT1,
FT                                ECO:0000269|PubMed:17698003,
FT                                ECO:0000269|PubMed:17914902}.
FT   NP_BIND     132    134       ATP. {ECO:0000244|PDB:2P0E,
FT                                ECO:0000244|PDB:2QG6,
FT                                ECO:0000244|PDB:2QSY,
FT                                ECO:0000244|PDB:2QSZ,
FT                                ECO:0000244|PDB:2QT0,
FT                                ECO:0000244|PDB:2QT1,
FT                                ECO:0000269|PubMed:17698003,
FT                                ECO:0000269|PubMed:17914902}.
FT   NP_BIND     172    174       ATP. {ECO:0000244|PDB:2QSY,
FT                                ECO:0000244|PDB:2QT0,
FT                                ECO:0000269|PubMed:17914902}.
FT   REGION       36     39       Substrate binding. {ECO:0000244|PDB:2P0E,
FT                                ECO:0000244|PDB:2QL6,
FT                                ECO:0000244|PDB:2QT0,
FT                                ECO:0000244|PDB:2QT1,
FT                                ECO:0000269|PubMed:17698003,
FT                                ECO:0000269|PubMed:17914902}.
FT   REGION       55     56       Substrate binding. {ECO:0000244|PDB:2P0E,
FT                                ECO:0000244|PDB:2QL6,
FT                                ECO:0000244|PDB:2QT0,
FT                                ECO:0000244|PDB:2QT1,
FT                                ECO:0000269|PubMed:17698003,
FT                                ECO:0000269|PubMed:17914902}.
FT   REGION      134    135       Substrate binding. {ECO:0000244|PDB:2P0E,
FT                                ECO:0000244|PDB:2QL6,
FT                                ECO:0000244|PDB:2QT0,
FT                                ECO:0000269|PubMed:17698003,
FT                                ECO:0000269|PubMed:17914902}.
FT   ACT_SITE     36     36       Proton acceptor. {ECO:0000244|PDB:2QT0,
FT                                ECO:0000269|PubMed:17914902}.
FT   METAL        17     17       Magnesium. {ECO:0000244|PDB:2QSY,
FT                                ECO:0000269|PubMed:17914902}.
FT   METAL        36     36       Magnesium. {ECO:0000244|PDB:2QT0,
FT                                ECO:0000269|PubMed:17914902}.
FT   BINDING     128    128       ATP. {ECO:0000244|PDB:2P0E,
FT                                ECO:0000269|PubMed:17914902}.
FT   BINDING     129    129       Substrate. {ECO:0000244|PDB:2P0E,
FT                                ECO:0000244|PDB:2QL6,
FT                                ECO:0000244|PDB:2QT0,
FT                                ECO:0000244|PDB:2QT1,
FT                                ECO:0000269|PubMed:17914902}.
FT   VAR_SEQ     106    130       KPLDTIWNRSYFLTIPYEECKRRRS -> N (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_012676.
FT   MUTAGEN      16     16       K->A: Loss of activity.
FT                                {ECO:0000269|PubMed:17698003}.
FT   MUTAGEN      36     36       D->A: Loss of activity.
FT                                {ECO:0000269|PubMed:17698003,
FT                                ECO:0000269|PubMed:17914902}.
FT   MUTAGEN      56     56       D->A: Loss of activity.
FT                                {ECO:0000269|PubMed:17698003}.
FT   MUTAGEN      98     98       E->A: Loss of activity.
FT                                {ECO:0000269|PubMed:17914902}.
FT   MUTAGEN     138    138       D->A: Almost no effect.
FT                                {ECO:0000269|PubMed:17698003}.
FT   STRAND        4     11       {ECO:0000244|PDB:2QT1}.
FT   HELIX        16     24       {ECO:0000244|PDB:2QT1}.
FT   STRAND       30     34       {ECO:0000244|PDB:2QT1}.
FT   HELIX        35     38       {ECO:0000244|PDB:2QT1}.
FT   HELIX        42     44       {ECO:0000244|PDB:2QT1}.
FT   HELIX        58     60       {ECO:0000244|PDB:2QT1}.
FT   HELIX        63     77       {ECO:0000244|PDB:2QT1}.
FT   STRAND       94     98       {ECO:0000244|PDB:2QT1}.
FT   HELIX       106    108       {ECO:0000244|PDB:2QT1}.
FT   TURN        109    111       {ECO:0000244|PDB:2QT1}.
FT   STRAND      113    119       {ECO:0000244|PDB:2QT1}.
FT   HELIX       122    131       {ECO:0000244|PDB:2QT1}.
FT   HELIX       142    145       {ECO:0000244|PDB:2QT1}.
FT   HELIX       147    157       {ECO:0000244|PDB:2QT1}.
FT   HELIX       158    160       {ECO:0000244|PDB:2QT1}.
FT   STRAND      166    169       {ECO:0000244|PDB:2QT1}.
FT   HELIX       174    185       {ECO:0000244|PDB:2QT1}.
FT   TURN        186    188       {ECO:0000244|PDB:2QT1}.
SQ   SEQUENCE   199 AA;  23193 MW;  0A0803461F40EA32 CRC64;
     MKTFIIGISG VTNSGKTTLA KNLQKHLPNC SVISQDDFFK PESEIETDKN GFLQYDVLEA
     LNMEKMMSAI SCWMESARHS VVSTDQESAE EIPILIIEGF LLFNYKPLDT IWNRSYFLTI
     PYEECKRRRS TRVYQPPDSP GYFDGHVWPM YLKYRQEMQD ITWEVVYLDG TKSEEDLFLQ
     VYEDLIQELA KQKCLQVTA
//
